Evidence map›Paper›PMID 39990945›Full record

ArticleACS bio & med chem Au2025

NIR-Responsive Black Phosphorus Nanosheet-Integrated Niosomes for Combinatorial Chemo-phototherapy of Cancers.

Rahul Kumar, Shubham Kumar Singh, Rishabh Kumar Srivastava, Subhrajyoti Mallick, Raviraj Vankayala

Abstract read
In one paragraph

Article in ACS bio & med chem Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rahul KumarDepartment of Bioscience and Bioengineering, Indian Institute of Technology Jodhpur, Karwar 342030, India.
Shubham Kumar SinghDepartment of Bioscience and Bioengineering, Indian Institute of Technology Jodhpur, Karwar 342030, India.
Rishabh Kumar SrivastavaDepartment of Bioscience and Bioengineering, Indian Institute of Technology Jodhpur, Karwar 342030, India.
Subhrajyoti MallickDepartment of Bioscience and Bioengineering, Indian Institute of Technology Jodhpur, Karwar 342030, India.ORCID https://orcid.org/0009-0006-0408-7619
Raviraj VankayalaDepartment of Bioscience and Bioengineering, Indian Institute of Technology Jodhpur, Karwar 342030, India.ORCID https://orcid.org/0000-0002-4661-066X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains one of the major challenges in the field of clinical biomedicine. There is a great deal of scope for the development of various innovative therapies. To advance in the field of cancer therapeutics, the research trend has gradually shifted to the development of biocompatible, controlled, and stable carrier systems. To address such issues, herein, we report NIR-responsive black phosphorus (BP) nanosheet-integrated niosomes to mediate chemo-phototherapy of cancers. Niosome-coated black phosphorus nanosheets loaded with indocyanine green (ICG) and doxorubicin (DOX) (NBID) exhibit very high drug loading efficiency (>90%). Upon 808 nm NIR light irradiation, the NBID system initiates combinatorial effects where heat generation induced from BP nanosheets and ICG disrupts the niosomal coating, facilitating the controlled release of ICG and DOX in a pH- and light dual-responsive manner. This combinatorial approach induces DNA damage in cancer cells via DOX and also triggers photothermal (PTT) and photodynamic (PDT) effects, significantly enhancing tumor eradication. In a 2D cell culture model, the NBID formulation demonstrates excellent cytocompatibility in the dark, effective tumor cell uptake, and tumor cell death, showing potential for further application. To mimic the cancer microenvironment even more closely, the NBID nanoformulation has been tested against the 3D tumor spheroids, where NBID formulation shows tumor uptake and causes cancer cell death. The therapeutic efficacy of the NBID system can be controlled by laser, proving its light-responsive behavior to kill cancer cells in vitro. This integrated approach using NBID as a potent platform for combinatorial cancer therapy offers a promising advancement in achieving a safer, controlled, and stable drug delivery system.

Identifiers

PMID39990945
PMCPMC11843328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.